Endothelial dysfunction in heart failure with normal systolic function, and its correction with a metabolic agent, mildronate
To assess the influence of a metabolic agent, mildronate, on endothelial function in chronic heart failure (CHF) with normal systolic function, 105 patients with I-IIA Stage, II-III Functional Class (FC) CHF, and normal left ventricular systolic function, were examined. CHF developed as a result of...
Saved in:
Main Authors: | V. P. Geychenko, A. V. Kuryata, O. V. Muzhchil |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2005-08-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2403 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CYTOPROTECTOR MILDRONATE IN CORRECTING MYOCARDIAL DYSFUNCTION AMONG STABLE ANGINA PATIENTS AFTER CORONARY REVASCULARISATION
by: I. G. Gordeev, et al.
Published: (2009-04-01) -
MILDRONATE POTENTIAL FOR CORRECTING COGNITIVE DYSFUNCTION IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION
by: M. E. Statsenko, et al.
Published: (2011-08-01) -
ENDOTHELIAL DYSFUNCTION AND ITS CORRECTION WIT CYTOPROTECTORS IN PATIENTS WITH STABLE EFFORT ANGINA AND ARTERIAL HYPERTENSION
by: F. E. Khlebodarov, et al.
Published: (2009-12-01) -
Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives
by: V. P. Mikhin, et al.
Published: (2012-02-01) -
Noliprel and endothelial dysfunction correction in metabolic syndrome patients
by: V. V. Trusov, et al.
Published: (2005-12-01)